PSTX - Positive Early Phase 1 Trial Results has the Listing Trading Higher

2023-12-11 08:02:38 ET

DENVER, Colo., Dec 11, 2023 ( www.247marketnews.com )- Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported, Sunday evening, early efficacy and safety results from its Phase 1 study of P-BCMA-ALLO1, its BCMA-targeted allogeneic, T stem cell memory (TSCM)-rich chimeric antigen receptor (CAR)-T therapy candidate, which Poseida is investigating in partnership with Roche for the treatment of relapsed/refractory multiple myeloma (RRMM).

Highlights include; 82% ORR and deep clinical responses from off-the-shelf, allogeneic BCMA-targeted CAR-T in heavily pretreated patients receiving adequate lymphodepletion; 100% ORR in these patients who were not previously treated with a BCMA-targeted bispecific T cell-engaging antibody; Favorable emerging safety and reliability profile, with all (100%) intent-to-treat (ITT) patients receiving therapy, no GvHD or dose-limiting toxicities and low incidences of CRS and …

The post Positive Early Phase 1 Trial Results has the Listing Trading Higher appeared first on 24/7 Market News .

For further details see: